AbbVie (ABBV) director Jennifer L. Davis granted 1,118 restricted stock units as equity pay

Rhea-AI Filing Summary

AbbVie Inc. director Jennifer L. Davis received an equity-based compensation award rather than buying shares on the market. She was granted 1,118 restricted stock units under AbbVie’s Amended and Restated 2013 Incentive Stock Program, increasing her reported direct holdings to 3,643 common shares. These units will convert into AbbVie stock on a one-to-one basis upon her separation from service, death, or a qualifying change in control, aligning her compensation more closely with long-term shareholder value.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Davis Jennifer L.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.01 par value	1,118	$0.00	--

Holdings After Transaction: Common Stock, $0.01 par value — 3,643 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock units granted: 1,118 units Shares after transaction: 3,643 shares Price per share for grant: $0.00 per share

3 metrics

Restricted stock units granted 1,118 units Equity award to director on May 8, 2026

Shares after transaction 3,643 shares Total AbbVie common stock reported as directly held

Price per share for grant $0.00 per share Compensation grant, not a market purchase

Key Terms

restricted stock units, Amended and Restated 2013 Incentive Stock Program, change in control

3 terms

restricted stock units financial

"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated 2013 Incentive Stock Program financial

"awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program")"

change in control financial

"on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Jennifer L.

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	05/08/2026		A		1,118(1)	A	$0	3,643	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ T.O. Odutayo, Attorney-in-Fact for Jennifer L. Davis	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AbbVie (ABBV) director Jennifer L. Davis report in this Form 4?

AbbVie director Jennifer L. Davis reported receiving 1,118 restricted stock units as an equity award. These units were granted under AbbVie’s 2013 Incentive Stock Program and represent compensation, not an open-market stock purchase, increasing her reported direct holdings to 3,643 common shares.

Is Jennifer L. Davis buying or selling AbbVie (ABBV) shares in this filing?

Jennifer L. Davis is not buying or selling AbbVie shares on the market in this filing. She received 1,118 restricted stock units as a grant under AbbVie’s incentive program, which will later convert into common shares upon specific triggering events.

How many AbbVie (ABBV) restricted stock units did Jennifer L. Davis receive?

Jennifer L. Davis received 1,118 restricted stock units from AbbVie. These units are part of the AbbVie Amended and Restated 2013 Incentive Stock Program and will be settled in an equal number of AbbVie common shares when certain conditions, such as separation or change in control, occur.

What are Jennifer L. Davis’s AbbVie (ABBV) holdings after this Form 4 transaction?

After this transaction, Jennifer L. Davis is reported to hold 3,643 AbbVie common shares directly. This total reflects the impact of the 1,118 restricted stock units granted, which are structured to convert into shares at specified future events outlined in the incentive program.

How do the AbbVie (ABBV) restricted stock units for Jennifer L. Davis vest or pay out?

The restricted stock units granted to Jennifer L. Davis will be paid in AbbVie common stock on a one-to-one basis. Payment occurs upon the earlier of her separation from service, death, or a defined change in control under AbbVie’s Amended and Restated 2013 Incentive Stock Program.